ID   EPHA3_HUMAN             Reviewed;         983 AA.
AC   P29320; Q9H2V3; Q9H2V4;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   10-MAY-2017, entry version 189.
DE   RecName: Full=Ephrin type-A receptor 3;
DE            EC=2.7.10.1;
DE   AltName: Full=EPH-like kinase 4;
DE            Short=EK4;
DE            Short=hEK4;
DE   AltName: Full=HEK;
DE            Short=Human embryo kinase;
DE   AltName: Full=Tyrosine-protein kinase TYRO4;
DE   AltName: Full=Tyrosine-protein kinase receptor ETK1;
DE            Short=Eph-like tyrosine kinase 1;
DE   Flags: Precursor;
GN   Name=EPHA3; Synonyms=ETK, ETK1, HEK, TYRO4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-924.
RX   PubMed=1311845; DOI=10.1073/pnas.89.5.1611;
RA   Wicks I.P., Wilkinson D., Salvaris E., Boyd A.W.;
RT   "Molecular cloning of HEK, the gene encoding a receptor tyrosine
RT   kinase expressed by human lymphoid tumor cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:1611-1615(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Melanoma;
RX   PubMed=10987298;
RA   Chiari R., Hames G., Stroobant V., Texier C., Maillere B., Boon T.,
RA   Coulie P.G.;
RT   "Identification of a tumor-specific shared antigen derived from an Eph
RT   receptor and presented to CD4 T cells on HLA class II molecules.";
RL   Cancer Res. 60:4855-4863(2000).
RN   [3]
RP   PROTEIN SEQUENCE OF 21-29 AND 840-860, AND CHARACTERIZATION.
RX   PubMed=1737782;
RA   Boyd A.W., Ward L.D., Wicks I.P., Simpson R.J., Salvaris E., Wilks A.,
RA   Welch K., Loudovaris M., Rockman S., Busmanis I.;
RT   "Isolation and characterization of a novel receptor-type protein
RT   tyrosine kinase (hek) from a human pre-B cell line.";
RL   J. Biol. Chem. 267:3262-3267(1992).
RN   [4]
RP   NOMENCLATURE.
RX   PubMed=9267020;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [5]
RP   FUNCTION IN CELL-CELL ADHESION, EFNA5-BINDING, SUBCELLULAR LOCATION
RP   (ISOFORM 1), INTERACTION WITH CRK, AND PHOSPHORYLATION AT TYR-596;
RP   TYR-602 AND TYR-779.
RX   PubMed=11870224;
RA   Lawrenson I.D., Wimmer-Kleikamp S.H., Lock P., Schoenwaelder S.M.,
RA   Down M., Boyd A.W., Alewood P.F., Lackmann M.;
RT   "Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-
RT   expressing 293T and melanoma cells by CrkII and Rho-mediated
RT   signalling.";
RL   J. Cell Sci. 115:1059-1072(2002).
RN   [6]
RP   INVOLVEMENT IN CRC.
RX   PubMed=12738854; DOI=10.1126/science.1082596;
RA   Bardelli A., Parsons D.W., Silliman N., Ptak J., Szabo S., Saha S.,
RA   Markowitz S., Willson J.K., Parmigiani G., Kinzler K.W.,
RA   Vogelstein B., Velculescu V.E.;
RT   "Mutational analysis of the tyrosine kinome in colorectal cancers.";
RL   Science 300:949-949(2003).
RN   [7]
RP   EPHRIN LIGAND-BINDING, OLIGOMERIZATION, MUTAGENESIS OF VAL-133 AND
RP   PHE-152, AND INTERACTION WITH CRK.
RX   PubMed=14660665; DOI=10.1074/jbc.M309326200;
RA   Smith F.M., Vearing C., Lackmann M., Treutlein H., Himanen J.,
RA   Chen K., Saul A., Nikolov D., Boyd A.W.;
RT   "Dissecting the EphA3/Ephrin-A5 interactions using a novel functional
RT   mutagenesis screen.";
RL   J. Biol. Chem. 279:9522-9531(2004).
RN   [8]
RP   IDENTIFICATION IN A COMPLEX WITH ADAM10 AND EFNA5.
RX   PubMed=16239146; DOI=10.1016/j.cell.2005.08.014;
RA   Janes P.W., Saha N., Barton W.A., Kolev M.V., Wimmer-Kleikamp S.H.,
RA   Nievergall E., Blobel C.P., Himanen J.P., Lackmann M., Nikolov D.B.;
RT   "Adam meets Eph: an ADAM substrate recognition module acts as a
RT   molecular switch for ephrin cleavage in trans.";
RL   Cell 123:291-304(2005).
RN   [9]
RP   EFNA5 LIGAND-BINDING.
RX   PubMed=15901737; DOI=10.1074/jbc.M504972200;
RA   Day B., To C., Himanen J.P., Smith F.M., Nikolov D.B., Boyd A.W.,
RA   Lackmann M.;
RT   "Three distinct molecular surfaces in ephrin-A5 are essential for a
RT   functional interaction with EphA3.";
RL   J. Biol. Chem. 280:26526-26532(2005).
RN   [10]
RP   INTERACTION WITH PTPN1, PHOSPHORYLATION, DEPHOSPHORYLATION BY PTPN1,
RP   AND SUBCELLULAR LOCATION (ISOFORM 2).
RX   PubMed=21135139; DOI=10.1083/jcb.201005035;
RA   Nievergall E., Janes P.W., Stegmayer C., Vail M.E., Haj F.G.,
RA   Teng S.W., Neel B.G., Bastiaens P.I., Lackmann M.;
RT   "PTP1B regulates Eph receptor function and trafficking.";
RL   J. Cell Biol. 191:1189-1203(2010).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.07 ANGSTROMS) OF 577-947 IN COMPLEX WITH ATP
RP   ANALOG, IDENTIFICATION BY MASS SPECTROMETRY, PHOSPHORYLATION AT
RP   TYR-596; TYR-602 AND TYR-701, AND MUTAGENESIS OF TYR-596; TYR-602;
RP   TYR-742 AND SER-768.
RX   PubMed=18547520; DOI=10.1016/j.str.2008.03.008;
RA   Davis T.L., Walker J.R., Loppnau P., Butler-Cole C.,
RA   Allali-Hassani A., Dhe-Paganon S.;
RT   "Autoregulation by the juxtamembrane region of the human ephrin
RT   receptor tyrosine kinase A3 (EphA3).";
RL   Structure 16:873-884(2008).
RN   [12]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-37; SER-85; LEU-621 AND ASN-806.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [13]
RP   VARIANTS LYS-660 AND MET-933.
RX   PubMed=16941478; DOI=10.1002/humu.9452;
RA   Wood L.D., Calhoun E.S., Silliman N., Ptak J., Szabo S., Powell S.M.,
RA   Riggins G.J., Wang T.L., Yan H., Gazdar A., Kern S.E., Pennacchio L.,
RA   Kinzler K.W., Vogelstein B., Velculescu V.E.;
RT   "Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers.";
RL   Hum. Mutat. 27:1060-1061(2006).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] TYR-229; PHE-449; LEU-518; VAL-564;
RP   SER-568; PRO-590; GLU-766; GLY-777; HIS-914 AND ARG-924.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [15]
RP   VARIANT ASN-207.
RX   PubMed=20838624; DOI=10.1371/journal.pone.0012653;
RA   Corbo V., Ritelli R., Barbi S., Funel N., Campani D., Bardelli A.,
RA   Scarpa A.;
RT   "Mutational profiling of kinases in human tumours of pancreatic origin
RT   identifies candidate cancer genes in ductal and ampulla of vater
RT   carcinomas.";
RL   PLoS ONE 5:E12653-E12653(2010).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously
CC       membrane-bound ephrin family ligands residing on adjacent cells,
CC       leading to contact-dependent bidirectional signaling into
CC       neighboring cells. The signaling pathway downstream of the
CC       receptor is referred to as forward signaling while the signaling
CC       pathway downstream of the ephrin ligand is referred to as reverse
CC       signaling. Highly promiscuous for ephrin-A ligands it binds
CC       preferentially EFNA5. Upon activation by EFNA5 regulates cell-cell
CC       adhesion, cytoskeletal organization and cell migration. Plays a
CC       role in cardiac cells migration and differentiation and regulates
CC       the formation of the atrioventricular canal and septum during
CC       development probably through activation by EFNA1. Involved in the
CC       retinotectal mapping of neurons. May also control the segregation
CC       but not the guidance of motor and sensory axons during
CC       neuromuscular circuit development. {ECO:0000269|PubMed:11870224}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Heterotetramer upon binding of the ligand. The
CC       heterotetramer is composed of an ephrin dimer and a receptor
CC       dimer. Oligomerization is probably required to induce biological
CC       responses. Forms a ternary EFNA5-EPHA3-ADAM10 complex mediating
CC       EFNA5 extracellular domain shedding by ADAM10 which regulates the
CC       EFNA5-EPHA3 complex internalization and function. Interacts with
CC       NCK1 (via SH2 domain); mediates EFNA5-EPHA3 signaling (By
CC       similarity). Interacts (phosphorylated) with PTPN1;
CC       dephosphorylates EPHA3 and may regulate its trafficking and
CC       function. Interacts (phosphorylated) with CRK; mediates EFNA5-
CC       EPHA3 signaling through RHOA GTPase activation. {ECO:0000250,
CC       ECO:0000269|PubMed:11870224, ECO:0000269|PubMed:14660665,
CC       ECO:0000269|PubMed:16239146, ECO:0000269|PubMed:18547520,
CC       ECO:0000269|PubMed:21135139}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane
CC       {ECO:0000269|PubMed:11870224}; Single-pass type I membrane protein
CC       {ECO:0000255}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted
CC       {ECO:0000269|PubMed:21135139}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P29320-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P29320-2; Sequence=VSP_002995, VSP_002996;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Highest level in placenta.
CC   -!- PTM: Autophosphorylates upon activation by EFNA5. Phosphorylation
CC       on Tyr-602 mediates interaction with NCK1. Dephosphorylated by
CC       PTPN1. {ECO:0000269|PubMed:11870224, ECO:0000269|PubMed:18547520,
CC       ECO:0000269|PubMed:21135139}.
CC   -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease
CC       characterized by malignant lesions arising from the inner wall of
CC       the large intestine (the colon) and the rectum. Genetic
CC       alterations are often associated with progression from
CC       premalignant lesion (adenoma) to invasive adenocarcinoma. Risk
CC       factors for cancer of the colon and rectum include colon polyps,
CC       long-standing ulcerative colitis, and genetic family history.
CC       {ECO:0000269|PubMed:12738854}. Note=The gene represented in this
CC       entry may be involved in disease pathogenesis.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EPHA3ID40463ch3p11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M83941; AAA58633.1; -; mRNA.
DR   EMBL; AF213459; AAG43576.1; -; mRNA.
DR   EMBL; AF213460; AAG43577.1; -; mRNA.
DR   CCDS; CCDS2922.1; -. [P29320-1]
DR   CCDS; CCDS46875.1; -. [P29320-2]
DR   PIR; A38224; A38224.
DR   RefSeq; NP_005224.2; NM_005233.5. [P29320-1]
DR   RefSeq; NP_872585.1; NM_182644.2. [P29320-2]
DR   UniGene; Hs.123642; -.
DR   PDB; 2GSF; X-ray; 1.77 A; A=577-947.
DR   PDB; 2QO2; X-ray; 1.60 A; A=577-947.
DR   PDB; 2QO7; X-ray; 1.60 A; A=577-947.
DR   PDB; 2QO9; X-ray; 1.55 A; A=577-947.
DR   PDB; 2QOB; X-ray; 1.65 A; A=609-947.
DR   PDB; 2QOC; X-ray; 1.25 A; A=609-947.
DR   PDB; 2QOD; X-ray; 1.15 A; A=577-947.
DR   PDB; 2QOF; X-ray; 1.20 A; A=577-947.
DR   PDB; 2QOI; X-ray; 1.25 A; A=577-947.
DR   PDB; 2QOK; X-ray; 1.20 A; A=577-947.
DR   PDB; 2QOL; X-ray; 1.07 A; A=577-947.
DR   PDB; 2QON; X-ray; 1.79 A; A=577-947.
DR   PDB; 2QOO; X-ray; 1.25 A; A=577-947.
DR   PDB; 2QOQ; X-ray; 1.60 A; A=577-947.
DR   PDB; 3DZQ; X-ray; 1.75 A; A=609-947.
DR   PDB; 3FXX; X-ray; 1.70 A; A=577-947.
DR   PDB; 3FY2; X-ray; 1.80 A; A=577-947.
DR   PDB; 4G2F; X-ray; 1.70 A; A=609-947.
DR   PDB; 4GK2; X-ray; 2.20 A; A=609-947.
DR   PDB; 4GK3; X-ray; 1.90 A; A=609-947.
DR   PDB; 4GK4; X-ray; 2.10 A; A=609-947.
DR   PDB; 4L0P; X-ray; 2.26 A; A=29-201.
DR   PDB; 4P4C; X-ray; 1.60 A; A=609-947.
DR   PDB; 4P5Q; X-ray; 1.35 A; A=606-947.
DR   PDB; 4P5Z; X-ray; 2.00 A; A=606-947.
DR   PDB; 4TWN; X-ray; 1.71 A; A=609-947.
DR   PDB; 4TWO; X-ray; 2.05 A; A=609-947.
DR   PDBsum; 2GSF; -.
DR   PDBsum; 2QO2; -.
DR   PDBsum; 2QO7; -.
DR   PDBsum; 2QO9; -.
DR   PDBsum; 2QOB; -.
DR   PDBsum; 2QOC; -.
DR   PDBsum; 2QOD; -.
DR   PDBsum; 2QOF; -.
DR   PDBsum; 2QOI; -.
DR   PDBsum; 2QOK; -.
DR   PDBsum; 2QOL; -.
DR   PDBsum; 2QON; -.
DR   PDBsum; 2QOO; -.
DR   PDBsum; 2QOQ; -.
DR   PDBsum; 3DZQ; -.
DR   PDBsum; 3FXX; -.
DR   PDBsum; 3FY2; -.
DR   PDBsum; 4G2F; -.
DR   PDBsum; 4GK2; -.
DR   PDBsum; 4GK3; -.
DR   PDBsum; 4GK4; -.
DR   PDBsum; 4L0P; -.
DR   PDBsum; 4P4C; -.
DR   PDBsum; 4P5Q; -.
DR   PDBsum; 4P5Z; -.
DR   PDBsum; 4TWN; -.
DR   PDBsum; 4TWO; -.
DR   ProteinModelPortal; P29320; -.
DR   SMR; P29320; -.
DR   BioGrid; 108356; 21.
DR   DIP; DIP-40307N; -.
DR   IntAct; P29320; 5.
DR   MINT; MINT-7145005; -.
DR   STRING; 9606.ENSP00000337451; -.
DR   BindingDB; P29320; -.
DR   ChEMBL; CHEMBL4954; -.
DR   GuidetoPHARMACOLOGY; 1823; -.
DR   iPTMnet; P29320; -.
DR   PhosphoSitePlus; P29320; -.
DR   BioMuta; EPHA3; -.
DR   DMDM; 116241351; -.
DR   MaxQB; P29320; -.
DR   PaxDb; P29320; -.
DR   PeptideAtlas; P29320; -.
DR   PRIDE; P29320; -.
DR   DNASU; 2042; -.
DR   Ensembl; ENST00000336596; ENSP00000337451; ENSG00000044524. [P29320-1]
DR   Ensembl; ENST00000452448; ENSP00000399926; ENSG00000044524. [P29320-2]
DR   GeneID; 2042; -.
DR   KEGG; hsa:2042; -.
DR   UCSC; uc003dqx.2; human. [P29320-1]
DR   CTD; 2042; -.
DR   DisGeNET; 2042; -.
DR   GeneCards; EPHA3; -.
DR   HGNC; HGNC:3387; EPHA3.
DR   HPA; CAB010462; -.
DR   MIM; 114500; phenotype.
DR   MIM; 179611; gene.
DR   neXtProt; NX_P29320; -.
DR   OpenTargets; ENSG00000044524; -.
DR   PharmGKB; PA27819; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118975; -.
DR   HOGENOM; HOG000233856; -.
DR   HOVERGEN; HBG062180; -.
DR   InParanoid; P29320; -.
DR   KO; K05104; -.
DR   OMA; SHGWEEI; -.
DR   OrthoDB; EOG091G00W0; -.
DR   PhylomeDB; P29320; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P29320; -.
DR   SIGNOR; P29320; -.
DR   EvolutionaryTrace; P29320; -.
DR   GeneWiki; EPH_receptor_A3; -.
DR   GenomeRNAi; 2042; -.
DR   PRO; PR:P29320; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000044524; -.
DR   CleanEx; HS_EPHA3; -.
DR   ExpressionAtlas; P29320; baseline and differential.
DR   Genevisible; P29320; HS.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; IDA:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0016477; P:cell migration; ISS:UniProtKB.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0097156; P:fasciculation of motor neuron axon; ISS:UniProtKB.
DR   GO; GO:0097155; P:fasciculation of sensory neuron axon; ISS:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; ISS:UniProtKB.
DR   GO; GO:0051893; P:regulation of focal adhesion assembly; IDA:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IDA:UniProtKB.
DR   CDD; cd10481; EphR_LBD_A3; 1.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR034266; EphA3_rcpt_lig-bd.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF07699; Ephrin_rec_like; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM01411; Ephrin_rec_like; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion;
KW   Cell membrane; Complete proteome; Direct protein sequencing;
KW   Glycoprotein; Kinase; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Repeat; Secreted; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     20       {ECO:0000269|PubMed:1737782}.
FT   CHAIN        21    983       Ephrin type-A receptor 3.
FT                                /FTId=PRO_0000016802.
FT   TOPO_DOM     21    541       Extracellular. {ECO:0000255}.
FT   TRANSMEM    542    565       Helical. {ECO:0000255}.
FT   TOPO_DOM    566    983       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       29    207       Eph LBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00883}.
FT   DOMAIN      325    435       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      436    531       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      621    882       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      911    975       SAM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00184}.
FT   NP_BIND     628    633       ATP.
FT   NP_BIND     700    706       ATP.
FT   NP_BIND     750    751       ATP.
FT   MOTIF       981    983       PDZ-binding. {ECO:0000255}.
FT   COMPBIAS    189    322       Cys-rich.
FT   ACT_SITE    746    746       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     653    653       ATP.
FT   MOD_RES     596    596       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11870224,
FT                                ECO:0000269|PubMed:18547520}.
FT   MOD_RES     602    602       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11870224,
FT                                ECO:0000269|PubMed:18547520}.
FT   MOD_RES     701    701       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18547520}.
FT   MOD_RES     779    779       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11870224}.
FT   MOD_RES     937    937       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P29319}.
FT   CARBOHYD    232    232       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    337    337       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    391    391       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    404    404       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    493    493       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ     532    539       SFSISGES -> CMYYFNAV (in isoform 2).
FT                                {ECO:0000303|PubMed:10987298}.
FT                                /FTId=VSP_002995.
FT   VAR_SEQ     540    983       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10987298}.
FT                                /FTId=VSP_002996.
FT   VARIANT      37     37       T -> K (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036086.
FT   VARIANT      85     85       N -> S (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036087.
FT   VARIANT     207    207       K -> N (in a pancreatic ductal
FT                                adenocarcinoma sample; somatic mutation;
FT                                dbSNP:rs200567888).
FT                                {ECO:0000269|PubMed:20838624}.
FT                                /FTId=VAR_068853.
FT   VARIANT     229    229       S -> Y (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042126.
FT   VARIANT     449    449       S -> F (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042127.
FT   VARIANT     518    518       G -> L (in a lung squamous cell carcinoma
FT                                sample; somatic mutation; requires 2
FT                                nucleotide substitutions).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042128.
FT   VARIANT     564    564       I -> V (in dbSNP:rs55712516).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042129.
FT   VARIANT     568    568       C -> S (in dbSNP:rs56077781).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042130.
FT   VARIANT     590    590       L -> P (in dbSNP:rs56081642).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042131.
FT   VARIANT     621    621       I -> L (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036088.
FT   VARIANT     660    660       T -> K (in a lung carcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16941478}.
FT                                /FTId=VAR_065831.
FT   VARIANT     766    766       G -> E (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042132.
FT   VARIANT     777    777       A -> G (in dbSNP:rs34437982).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042133.
FT   VARIANT     806    806       D -> N (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036089.
FT   VARIANT     914    914       R -> H (in dbSNP:rs17801309).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_027919.
FT   VARIANT     924    924       W -> R (in dbSNP:rs35124509).
FT                                {ECO:0000269|PubMed:1311845,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042134.
FT   VARIANT     933    933       T -> M (in a lung carcinoma sample;
FT                                somatic mutation; dbSNP:rs372594677).
FT                                {ECO:0000269|PubMed:16941478}.
FT                                /FTId=VAR_065832.
FT   MUTAGEN     133    133       V->E: Loss of EFNA5-binding ability and
FT                                function. {ECO:0000269|PubMed:14660665}.
FT   MUTAGEN     152    152       F->L: Loss of EFNA5-binding ability and
FT                                function. {ECO:0000269|PubMed:14660665}.
FT   MUTAGEN     596    596       Y->F: 10-fold suppression of kinase
FT                                activity; when associated with F-602.
FT                                Full kinase activity; when associated
FT                                with F-602 and F-742. Full kinase
FT                                activity; when associated with F-602 and
FT                                A-768. {ECO:0000269|PubMed:18547520}.
FT   MUTAGEN     602    602       Y->F: 10-fold suppression of kinase
FT                                activity; when associated with F-596.
FT                                Full kinase activity; when associated
FT                                with F-596 and F-742. Full kinase
FT                                activity; when associated with F-596 and
FT                                A-768. {ECO:0000269|PubMed:18547520}.
FT   MUTAGEN     742    742       Y->F: Full kinase activity; when
FT                                associated with F-596 and F-602.
FT                                {ECO:0000269|PubMed:18547520}.
FT   MUTAGEN     768    768       S->A: Full kinase activity; when
FT                                associated with F-596 and F-602.
FT                                {ECO:0000269|PubMed:18547520}.
FT   CONFLICT    911    911       T -> S (in Ref. 1; AAA58633).
FT                                {ECO:0000305}.
FT   STRAND       29     34       {ECO:0000244|PDB:4L0P}.
FT   TURN         38     41       {ECO:0000244|PDB:4L0P}.
FT   STRAND       45     48       {ECO:0000244|PDB:4L0P}.
FT   STRAND       51     58       {ECO:0000244|PDB:4L0P}.
FT   STRAND       64     71       {ECO:0000244|PDB:4L0P}.
FT   STRAND       75     77       {ECO:0000244|PDB:4L0P}.
FT   STRAND       80     83       {ECO:0000244|PDB:4L0P}.
FT   STRAND       96    104       {ECO:0000244|PDB:4L0P}.
FT   HELIX       106    108       {ECO:0000244|PDB:4L0P}.
FT   STRAND      117    128       {ECO:0000244|PDB:4L0P}.
FT   STRAND      130    132       {ECO:0000244|PDB:4L0P}.
FT   HELIX       137    139       {ECO:0000244|PDB:4L0P}.
FT   STRAND      141    147       {ECO:0000244|PDB:4L0P}.
FT   HELIX       154    159       {ECO:0000244|PDB:4L0P}.
FT   STRAND      165    170       {ECO:0000244|PDB:4L0P}.
FT   STRAND      176    200       {ECO:0000244|PDB:4L0P}.
FT   TURN        610    612       {ECO:0000244|PDB:2QOL}.
FT   HELIX       618    620       {ECO:0000244|PDB:2QOL}.
FT   STRAND      621    629       {ECO:0000244|PDB:2QOL}.
FT   STRAND      631    641       {ECO:0000244|PDB:2QOL}.
FT   STRAND      647    654       {ECO:0000244|PDB:2QOL}.
FT   HELIX       661    674       {ECO:0000244|PDB:2QOL}.
FT   STRAND      685    689       {ECO:0000244|PDB:2QOL}.
FT   STRAND      691    694       {ECO:0000244|PDB:2QOL}.
FT   STRAND      696    700       {ECO:0000244|PDB:2QOL}.
FT   HELIX       707    712       {ECO:0000244|PDB:2QOL}.
FT   TURN        713    716       {ECO:0000244|PDB:2QOL}.
FT   HELIX       720    739       {ECO:0000244|PDB:2QOL}.
FT   HELIX       749    751       {ECO:0000244|PDB:2QOL}.
FT   STRAND      752    754       {ECO:0000244|PDB:2QOL}.
FT   STRAND      760    762       {ECO:0000244|PDB:2QOL}.
FT   HELIX       765    768       {ECO:0000244|PDB:4TWN}.
FT   HELIX       788    790       {ECO:0000244|PDB:2QOD}.
FT   HELIX       793    798       {ECO:0000244|PDB:2QOL}.
FT   HELIX       803    818       {ECO:0000244|PDB:2QOL}.
FT   TURN        819    821       {ECO:0000244|PDB:2QO9}.
FT   TURN        824    827       {ECO:0000244|PDB:2QOL}.
FT   HELIX       830    838       {ECO:0000244|PDB:2QOL}.
FT   HELIX       851    860       {ECO:0000244|PDB:2QOL}.
FT   HELIX       865    867       {ECO:0000244|PDB:2QOL}.
FT   HELIX       871    883       {ECO:0000244|PDB:2QOL}.
FT   HELIX       885    889       {ECO:0000244|PDB:2QOL}.
FT   STRAND      890    892       {ECO:0000244|PDB:4G2F}.
FT   STRAND      898    903       {ECO:0000244|PDB:2QOC}.
SQ   SEQUENCE   983 AA;  110131 MW;  BE04DBF958245424 CRC64;
     MDCQLSILLL LSCSVLDSFG ELIPQPSNEV NLLDSKTIQG ELGWISYPSH GWEEISGVDE
     HYTPIRTYQV CNVMDHSQNN WLRTNWVPRN SAQKIYVELK FTLRDCNSIP LVLGTCKETF
     NLYYMESDDD HGVKFREHQF TKIDTIAADE SFTQMDLGDR ILKLNTEIRE VGPVNKKGFY
     LAFQDVGACV ALVSVRVYFK KCPFTVKNLA MFPDTVPMDS QSLVEVRGSC VNNSKEEDPP
     RMYCSTEGEW LVPIGKCSCN AGYEERGFMC QACRPGFYKA LDGNMKCAKC PPHSSTQEDG
     SMNCRCENNY FRADKDPPSM ACTRPPSSPR NVISNINETS VILDWSWPLD TGGRKDVTFN
     IICKKCGWNI KQCEPCSPNV RFLPRQFGLT NTTVTVTDLL AHTNYTFEID AVNGVSELSS
     PPRQFAAVSI TTNQAAPSPV LTIKKDRTSR NSISLSWQEP EHPNGIILDY EVKYYEKQEQ
     ETSYTILRAR GTNVTISSLK PDTIYVFQIR ARTAAGYGTN SRKFEFETSP DSFSISGESS
     QVVMIAISAA VAIILLTVVI YVLIGRFCGY KSKHGADEKR LHFGNGHLKL PGLRTYVDPH
     TYEDPTQAVH EFAKELDATN ISIDKVVGAG EFGEVCSGRL KLPSKKEISV AIKTLKVGYT
     EKQRRDFLGE ASIMGQFDHP NIIRLEGVVT KSKPVMIVTE YMENGSLDSF LRKHDAQFTV
     IQLVGMLRGI ASGMKYLSDM GYVHRDLAAR NILINSNLVC KVSDFGLSRV LEDDPEAAYT
     TRGGKIPIRW TSPEAIAYRK FTSASDVWSY GIVLWEVMSY GERPYWEMSN QDVIKAVDEG
     YRLPPPMDCP AALYQLMLDC WQKDRNNRPK FEQIVSILDK LIRNPGSLKI ITSAAARPSN
     LLLDQSNVDI TTFRTTGDWL NGVWTAHCKE IFTGVEYSSC DTIAKISTDD MKKVGVTVVG
     PQKKIISSIK ALETQSKNGP VPV
//
